Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
WuXi AppTec Co., Ltd. is a leading global provider of R&D and manufacturing services for the pharmaceutical, biotechnology, and medical device industries, with operations in China, the U.S., and Europe. The company differentiates itself through its integrated service model, offering end-to-end solutions that streamline the drug development process, thereby reducing time-to-market for clients.
WuXi AppTec generates revenue primarily through its laboratory and manufacturing services, leveraging its extensive network of facilities and skilled workforce. The company's competitive advantages include its scale, technological capabilities, and a robust client base that includes major pharmaceutical companies, which allows for pricing power and long-term contracts.
Growth in global pharmaceutical R&D spending
Expansion of manufacturing capacity in China and the U.S.
New service offerings and technological advancements
Regulatory approvals for client products
Regulatory changes affecting drug development processes
Technological disruption in R&D methodologies
Emergence of new players in the contract research organization (CRO) space
Pricing pressure from competitors offering similar services
Low liquidity risk due to a current ratio of 3.42
Potential risks from currency fluctuations given international operations
moderate - The company is somewhat sensitive to economic cycles as pharmaceutical R&D spending can fluctuate with economic conditions, but it also benefits from long-term contracts.
Interest rates affect WuXi AppTec primarily through the cost of capital for expansion and R&D investments. Rising rates could increase financing costs, potentially impacting growth plans and valuation multiples.
minimal - The company has a low debt-to-equity ratio of 0.10, indicating limited reliance on external financing.
growth - Investors are likely attracted to the company's strong revenue growth and high margins, indicating robust demand for its services.
moderate - The stock has shown significant returns recently, but its beta and historical volatility suggest a moderate risk profile.
